<!-- Biography -->

<section class="block" id="biography">
	<div class="content-wrapper"><h2><i class="fi-torso"></i>Biography</h2>
	<img class="profile-image" src="{{root}}/assets/img/ian-boyd.jpg" alt="Ian Boyd" />
	<p>Dr Ian Boyd began his career as a research chemist before becoming the Executive Officer of the Adverse Drug Reactions Unit of the Australian Therapeutics Goods Administration (<abbr data-tooltip aria-haspopup="true" class="has-tip" data-disable-hover="false" title="Therapeutic Goods Administration">TGA</abbr>), a position he held for 19 years until 2007. He was also Secretary of the Australian Adverse Drug Reactions Advisory Committee (<abbr data-tooltip aria-haspopup="true" class="has-tip" data-disable-hover="false" title="Adverse Drug Reactions Advisory Committee">ADRAC</abbr>) for 14 years. He has published widely in the area of pharmacovigilance as well as being a major contributor to the Australian Adverse Drug Reactions Bulletin which was the major flagship of <abbr data-tooltip aria-haspopup="true" class="has-tip" data-disable-hover="false" title="Adverse Drug Reactions Advisory Committee">ADRAC</abbr>. He has represented Australia at annual meetings of national centres participating in the WHO Drug Monitoring Programme on many occasions. More recently, he led the TGAâ€™s Adverse Drug Reactions Unit in the redevelopment of their IT infrastructure especially in the area of electronic lodgement of <abbr data-tooltip aria-haspopup="true" class="has-tip" data-disable-hover="false" title="Adverse Drug Reactions">ADRs</abbr>, conversion to <abbr data-tooltip aria-haspopup="true" class="has-tip" data-disable-hover="false" title="Medical Dictionary for Regulatory activities">MedDRA</abbr> and the development of reporting and analysis tools.</p>
	<p>In 2007 he formed Ian Boyd Consulting, a consultancy to advise European and Asia- Pacific clients in all areas relating to pharmacovigilance. During this time he has specialised in the preparation of Risk Management Plans (<abbr data-tooltip aria-haspopup="true" class="has-tip" data-disable-hover="false" title="Risk Management Plans">RMPs</abbr>) and Australian Specific Annexes (<abbr data-tooltip aria-haspopup="true" class="has-tip" data-disable-hover="false" title="Australian Specific Annexes">ASAs</abbr>).</p>
	<p>Dr Boyd is a peer reviewer for and a member of the Editorial Advisory Board of a number of international medical journals. He is also a member of the Uppsala Monitoring Centre Signal Review Panel and a former member of the Executive Committee of the International Society of Pharmacovigilance (<abbr data-tooltip aria-haspopup="true" class="has-tip" data-disable-hover="false" title="International Society of Pharmacovigilance">ISoP</abbr>).</p>
</div></section>
